









市场行情
/
股票
/
nasdaq-bdtx
/

Black Diamond Therapeutics Inc

BDTX

2.600USD

+0.060+2.36%

收盘 12/22, 16:00（美东）报价延迟15分钟

148.05M总市值

6.86市盈率 TTM



Black Diamond Therapeutics Inc

2.600

+0.060+2.36%

概览公司财务分析

概览

公司

财务

分析

关于 Black Diamond Therapeutics Inc 公司

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.

Black Diamond Therapeutics Inc简介



公司代码BDTX

公司名称Black Diamond Therapeutics Inc

上市日期Jan 30, 2020

CEOVelleca (Mark A)

员工数量24

证券类型Ordinary Share

年结日Jan 30

公司地址245 First Street, 18Th Floor

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话16174175868

网址https://www.blackdiamondtherapeutics.com/

公司代码BDTX

上市日期Jan 30, 2020

CEOVelleca (Mark A)

Black Diamond Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Erika Jones

Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer

85.15K

Dr. Ali Behbahani, M.D.

Independent Director

81.44K

+5.56%

Dr. Garry E. Menzel, Ph.D.

Independent Director

76.64K

-0.03%

Dr. Prakash Raman, Ph.D.

Independent Director

26.36K

+17.07%

Dr. Kapil Dhingra, M.D.

Independent Director

10.00K

Ms. Shannon Campbell

Independent Director

8.87K

Dr. Mark A. Velleca, M.D., Ph.D.

Chairman of the Board, President, Chief Executive Officer

Dr. Samarth Kulkarni, Ph.D.

Lead Independent Director

Dr. Sergey Yurasov, M.D., Ph.D.

Chief Medical Officer

-100.00%

Dr. Elizabeth Buck, Ph.D.

Co-Founder, Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Ms. Erika Jones

Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer

85.15K

Dr. Ali Behbahani, M.D.

Independent Director

81.44K

+5.56%

Dr. Garry E. Menzel, Ph.D.

Independent Director

76.64K

-0.03%

Dr. Prakash Raman, Ph.D.

Independent Director

26.36K

+17.07%

Dr. Kapil Dhingra, M.D.

Independent Director

10.00K

Ms. Shannon Campbell

Independent Director

8.87K

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

T. Rowe Price Investment Management, Inc.

18.86%

Versant Ventures

10.89%

Vestal Point Capital, LP

9.74%

New Enterprise Associates (NEA)

7.81%

The Vanguard Group, Inc.

3.84%

其他

48.86%

持股股东

占比

T. Rowe Price Investment Management, Inc.

18.86%

Versant Ventures

10.89%

Vestal Point Capital, LP

9.74%

New Enterprise Associates (NEA)

7.81%

The Vanguard Group, Inc.

3.84%

其他

48.86%

股东类型

持股股东

占比

Investment Advisor

30.99%

Investment Advisor/Hedge Fund

20.59%

Venture Capital

19.08%

Hedge Fund

7.50%

Research Firm

1.42%

Individual Investor

0.99%

Pension Fund

0.02%

其他

19.41%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

251

45.27M

104.04%

+4.70K

2025Q3

261

45.26M

106.75%

+270.69K

2025Q2

263

45.72M

119.11%

-2.33M

2025Q1

244

48.05M

134.35%

-28.07M

2024Q4

236

55.25M

127.86%

-855.91K

2024Q3

237

56.09M

121.86%

+1.99M

2024Q2

230

54.06M

101.77%

+8.09M

2024Q1

233

46.69M

117.14%

-13.89M

2023Q4

222

46.16M

104.70%

+1.30M

2023Q3

240

44.37M

104.97%

-4.12M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

T. Rowe Price Investment Management, Inc.

10.51M

18.46%

+112.89K

+1.09%

Jun 30, 2025

Versant Ventures

6.21M

10.9%

-221.60K

-3.45%

Apr 11, 2025

Vestal Point Capital, LP

5.60M

9.84%

Jun 30, 2025

New Enterprise Associates (NEA)

4.45M

7.81%

Jun 30, 2025

The Vanguard Group, Inc.

2.10M

3.69%

-253.80K

-10.77%

Jun 30, 2025

Tang Capital Management, LLC

2.07M

3.64%

Jun 30, 2025

Marshall Wace LLP

737.88K

1.3%

+737.88K

Jun 30, 2025

Invus Public Equities Advisors, LLC

1.05M

1.84%

Jun 30, 2025

Millennium Management LLC

944.85K

1.66%

-159.06K

-14.41%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Fidelity Enhanced Small Cap ETF

0.05%

iShares Micro-Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

DFA Dimensional US Small Cap Value ETF

iShares Russell 2000 Value ETF

iShares Health Innovation Active ETF

Vanguard US Momentum Factor ETF

ProShares Hedge Replication ETF

iShares Russell 2000 Growth ETF

Fidelity Enhanced Small Cap ETF

占比0.05%

iShares Micro-Cap ETF

占比0.03%

Avantis US Small Cap Equity ETF

占比0.02%

Invesco RAFI US 1500 Small-Mid ETF

占比0.01%

DFA Dimensional US Small Cap Value ETF

占比0%

iShares Russell 2000 Value ETF

占比0%

iShares Health Innovation Active ETF

占比0%

Vanguard US Momentum Factor ETF

占比0%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Black Diamond Therapeutics Inc的前五大股东是谁？



Black Diamond Therapeutics Inc 的前五大股东如下：
T. Rowe Price Investment Management, Inc.持有股份：10.51M，占总股份比例：18.46%。
Versant Ventures持有股份：6.21M，占总股份比例：10.90%。
Vestal Point Capital, LP持有股份：5.60M，占总股份比例：9.84%。
New Enterprise Associates (NEA)持有股份：4.45M，占总股份比例：7.81%。
The Vanguard Group, Inc.持有股份：2.10M，占总股份比例：3.69%。